AstraZeneca UK Limited

Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage (2024) Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Członkowska A, Lindgren AG, Molina CA, et al. Journal article Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy (2024) Zhou JG, Yang J, Wang H, Wong AHH, Tan F, Chen X, He SS, et al. Journal article Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real-world settings: Insights from REVEAL-CKD (2024) Tangri N, Alvarez CS, Arnold M, Barone S, Cebrián A, Chen H, De Nicola L, et al. Journal article Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study (2023) Tangri N, Moriyama T, Schneider M, Virgitti JB, De Nicola L, Arnold M, Barone S, et al. Journal article Mobilizing Patient and Public Involvement in the Development of Real-World Digital Technology Solutions: Tutorial. (2023) Keogh A, Ardle RM, Diaconu MG, Ammour N, Arnera V, Balzani F, Brittain G, et al. Journal article Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY (2023) Balmaña J, Fasching P, Couch FJ, Delaloge S, Labidi-Galy I, O’Shaughnessy J, Park YH, et al. Journal article Design and validation of a multi-task, multi-context protocol for real-world gait simulation (2022) Scott K, Bonci T, Salis F, Alcock L, Buckley E, Gazit E, Hansen C, et al. Journal article CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research (2022) Kotecha D, Asselbergs FW, Achenbach S, Anker SD, Atar D, Baigent C, Banerjee A, et al. Journal article Migratory and anti-fibrotic programmes define the regenerative potential of human cardiac progenitors (2022) Poch CM, Foo KS, De Angelis MT, Jennbacken K, Santamaria G, Baehr A, Wang QD, et al. Journal article Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis (2022) Balmana J, Fasching P, Delaloge S, Park YH, Eisen A, Bourgeois H, Kemp Z, et al. Conference contribution